Identification of a novel matrix metalloproteinases-related prognostic signature in hepatocellular carcinoma
View abstract on PubMed
Summary
This summary is machine-generated.A new matrix metalloproteinases (MMPs) signature predicts hepatocellular carcinoma (HCC) prognosis. This MMPs signature may improve HCC survival prediction and treatment strategies for liver cancer.
Area Of Science
- Oncology
- Molecular Biology
- Bioinformatics
Background
- Hepatocellular carcinoma (HCC) is a prevalent primary liver cancer globally.
- Matrix metalloproteinases (MMPs) influence cancer cell behaviors like infiltration and proliferation.
- The prognostic role of MMPs in HCC remains underexplored.
Purpose Of The Study
- To identify and validate a prognostic signature based on MMPs-related genes for HCC.
- To construct predictive models for overall survival (OS) in HCC patients.
- To explore the relationship between the MMPs signature, immune microenvironment, and drug sensitivity.
Main Methods
- Gene expression data from public databases were analyzed.
- Cox regression and LASSO Cox regression identified the prognostic signature.
- Nomograms, immune microenvironment analysis, and drug sensitivity analysis (GDSC) were performed.
Main Results
- A prognostic signature comprising RNPEPL1, ADAM15, ADAM18, ADAMTS5, CAD, YME1L1, AMZ2, PSMD15, and COPS6 was identified.
- Patients in the high-risk group exhibited significantly worse OS.
- High-risk group associated with increased M0/M2 macrophages and higher drug IC50 values for sorafenib, cisplatin, and cytarabine.
Conclusions
- A novel MMPs-related signature accurately predicts HCC prognosis.
- This signature offers potential for improved HCC prognosis predictability and treatment strategies.

